A Human Controlled Infection Study to Establish Safety of Infection With Bordetella Pertussis With Antibiotic Therapy Delayed for up to 6 Weeks

Status: Recruiting
Location: See location...
Intervention Type: Biological, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Primary objective- To assess the safety of nasal inoculation of healthy volunteers with B. pertussis with antibiotic therapy given to eradicate colonisation at 6 weeks after inoculation or at symptom onset, whichever occurs first Secondary objectives - To measure the rate of natural clearance of carriage of B. pertussis following nasal inoculation * To assess the kinetics of B. pertussis colonisation density following nasal inoculation * To describe the microevolution of B. pertussis and adaptation of the resident microbiome during B. pertussis carriage * To measure B. pertussis-specific antibody and cellular immunological responses in healthy volunteers during colonisation with B. pertussis - To identify biomarkers that correlate with natural clearance of B. pertussis carriage after induced B. pertussis colonisation * To detect transmission of B. pertussis to bedroom contacts of inoculated volunteers during prolonged asymptomatic colonisation

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: t
View:

• Healthy adults aged 18 to 55 years inclusive on the day of screening

• Fully conversant in the English language

• Able to communicate easily by both mobile telephone, email and text messaging

• Able and willing (in the investigator's opinion) to comply with all study requirements

• Written informed consent to participate in the study

• Willingness to take a curative antibiotic regimen if / when required according to the study protocol

• Willingness to abide by infection control guidelines during social contact for the duration of their participation in the study

• Willingness to attend to the National Institute for Health Research (NIHR) Clinical Research Facility (CRF) Southampton immediately if they become symptomatic

• Agreement to have no bedroom contacts other than their corresponding contact/challenge volunteer between inoculation and 6 weeks after inoculation

• Able to answer all questions on the pre-consent questionnaire correctly

Locations
Other Locations
United Kingdom
NIHR Clinical Research Facility
RECRUITING
Southampton
Contact Information
Primary
Robert Read
r.c.read@soton.ac.uk
023 8120 4989
Backup
Diane Gbesemete
d.gbesemete@soton.ac.uk
023 8120 4989
Time Frame
Start Date: 2022-12-06
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 72
Treatments
Other: Contact
Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A 3 day course of Azithromycin will be administered on week 6 if colonised.
Experimental: Challenge
Challenge volunteers will receive a nasal inoculation containing Bordetella pertussis on Day 0. They will return to the Clinical Research Facility weekly to monitor safety, colonisation and immune responses. A 3 day course of Azithromycin will be administered on week 6 if colonised.
Related Therapeutic Areas
Sponsors
Leads: University of Southampton

This content was sourced from clinicaltrials.gov